Pancreatic Cancer Breakthrough: New Drug Offers Hope

The Food and Drug Administration has approved Revolution Medicines' Rasonque, a novel drug offering new hope for patients with advanced pancreatic cancer. This groundbreaking medication is now available for individuals who have previously undergone treatments like chemotherapy.

Clinical trials demonstrated a remarkable improvement, with patients receiving Rasonque alongside standard chemotherapy living approximately twice as long, an average of 13.2 months, compared to those receiving only chemotherapy. This advancement is considered a major game-changer by oncologists.

Rasonque operates as a daily pill, specifically targeting a KRAS gene mutation. This mutation, which promotes uncontrolled cell growth, is present in nearly all pancreatic cancers and also occurs in lung, colorectal, and ovarian cancers, among others.

Pancreatic cancer, the third leading cause of cancer death in the U.S., is notoriously difficult to treat due to a lack of screening and vague early symptoms. The five-year survival rate for its most common form is a mere 8%.